Bullous pemphigoid (BP), which has no FDA-approved targeted therapies, leads to reddening of the skin and the formation of ...

with a recurrence of the skin eruption. He again denied the use of any medication prior to or during the present illness. Examination revealed vesicular and bullous lesions of the face ...

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

Bullous pemphigoid should be included in the differential diagnosis list of blistering skin lesions of the Yucatan minipig.

Patients with the urticarial form of BP may never develop typical BP bullae, but continue to exhibit skin lesions typical of urticarial dermatitis (Kossard, Hamann, & Wilkinson, 2006). Histologic ...

Bullous systemic lupus erythematosus ... (CLE): A form of lupus that primarily affects the skin, causing rashes and lesions.

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

Other causes of blisters include autoimmune health conditions such as bullous pemphigoid (when the immune system attacks the skin and causes ... blister-like lesions. Risk factors for blisters ...

First up is the ADEPT study in bullous pemphigoid (BP), a rare skin condition that leads to reddening of the skin and the formation of painful and intensely itchy chronic lesions and blisters ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...